The second-generation Arctic Front Advance cryoballoon achieved a higher long-term success rate compared to the first-generation balloon (86.7% vs 68.3%; p=0.017).
Cohort (n=120)
Does the second-generation cryoballoon improve long-term success and reduce procedural times compared to the first-generation cryoballoon in patients with paroxysmal atrial fibrillation?
The second-generation cryoballoon significantly improves long-term success rates and reduces procedural and fluoroscopy times compared to the first-generation device for paroxysmal AF ablation.
Absolute Event Rate: 86.7% vs 68.3%
p-value: p=0.017
Introduction. Cryoballoon (CB) ablation has emerged as a novel treatment for pulmonary vein isolation (PVI) for patients with paroxysmal atrial fibrillation (PAF). The second-generation Arctic Front Advance (ADV) was redesigned with technical modifications aiming at procedural and outcome improvements. We aimed to compare the efficacy of the two different technologies over a long-term follow-up. Methods. A total of 120 patients with PAF were enrolled. Sixty patients underwent PVI using the first-generation CB and 60 patients with the ADV catheter. All patients were evaluated over a follow-up period of 2 years. Results. There were no significant differences between the two groups of patients. Procedures performed with the first-generation CB showed longer fluoroscopy time (36.3 ± 16.8 versus 14.2 ± 13.5 min, resp.; p = 0.00016) and longer procedure times as well (153.1 ± 32 versus 102 ± 24.8 min, resp.; p = 0.019). The overall long-term success was significantly different between the two groups (68.3 versus 86.7%, resp.; p = 0.017). No differences were found in the lesion areas of left and right PV between the two groups (resp., p = 0.61 and 0.57). There were no significant differences in procedural-related complications. Conclusion. The ADV catheter compared to the first-generation balloon allows obtaining a significantly higher success rate after a single PVI procedure during the long-term follow-up. Fluoroscopy and procedural times were significantly shortened using the ADV catheter.
Conti et al. (Fri,) conducted a cohort in Paroxysmal Atrial Fibrillation (n=120). Second-generation Arctic Front Advance (ADV) cryoballoon vs. First-generation cryoballoon was evaluated on Overall long-term success (p=0.017). The second-generation Arctic Front Advance cryoballoon achieved a higher long-term success rate compared to the first-generation balloon (86.7% vs 68.3%; p=0.017).